Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Financial Results (Nov 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 5, 2025
Period End
November 5, 2025
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Leadership change8-K · Jan ’24Jan ’24

Summary

Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported third-quarter 2025 results for the quarter ended September 27, 2025, in a press release furnished under Item 2.02 as Exhibit 99.1.

Revenue was $1.00 billiona, a decrease of 0.5% from $1.01 billion a year earlier. Excluding a 1.3% favorable foreign currency impact and a 0.2% reduction from a divestiture, organic revenue declined 1.6%. GAAP earnings per diluted share were $1.10, compared with $1.33 in the prior-year quarter, primarily due to a $0.33 per share loss from venture capital and other strategic investments.

Non-GAAP diluted EPS was $2.43b, down 6.2% from $2.59. GAAP operating margin rose to 13.3% from 11.6%, driven by lower restructuring costs, while non-GAAP operating margin eased to 19.7% from 19.9%. By segment, Research Models and Services (RMS) grew revenue 7.9% to $213.5 million, with organic growth of 6.5% driven mainly by large research model products.

Discovery and Safety Assessment (DSA) revenue fell 2.3% to $600.7 millionc, with organic decline of 3.1% on lower discovery and regulated safety assessment volume. Manufacturing Solutions revenue fell 3.1% to $190.7 million, with organic decline of 5.1% led by CDMO and Biologics Testing, partly offset by Microbial Solutions. For 2025, the company narrowed its revenue and non-GAAP EPS guidance to the middle and upper ends of prior ranges, respectively.

Reported revenue growth is now guided at (1.5)% to (0.5)%, and non-GAAP EPS at $10.10 to $10.30d, versus the prior $9.90 to $10.30. GAAP EPS guidance is $4.15 to $4.35, down from $4.25 to $4.65 previously. Management stated that demand remains stable and some signals suggest the industry may be recovering, but sustained improvement will take time and the company remains cautious.

Key Highlights

  1. Q3 2025 revenue of $1.00 billion, down 0.5% from $1.01 billion; organic revenue declined 1.6%
  2. GAAP diluted EPS of $1.10 vs. $1.33 a year earlier, reflecting a $0.33 per share loss from venture capital and strategic investments; non-GAAP diluted EPS of $2.43 vs. $2.59 (down 6.2%)
  3. GAAP operating margin improved to 13.3% from 11.6%, primarily from lower restructuring costs; non-GAAP operating margin was 19.7% vs. 19.9%
  4. RMS revenue rose 7.9% to $213.5 million (organic growth of 6.5%), while DSA fell 2.3% to $600.7 million and Manufacturing fell 3.1% to $190.7 million
  5. 2025 non-GAAP EPS guidance narrowed to $10.10 to $10.30 (from $9.90 to $10.30); GAAP EPS guidance lowered to $4.15 to $4.35 (from $4.25 to $4.65)
  6. 2025 reported revenue growth guidance of (1.5)% to (0.5)%, with organic growth guided at (2.5)% to (1.5)%
  7. Non-GAAP adjustments include third-party legal costs tied to U.S. government investigations into the NHP supply chain and advisory costs related to a Cooperation Agreement with a shareholder

Frequently Asked Questions

  1. Why did GAAP EPS fall so much more than non-GAAP EPS in the third quarter?

    The decline in GAAP EPS was primarily driven by a loss of $0.33 per share from certain venture capital and other strategic investments, compared with a $0.03 per share gain in the prior-year quarter. Non-GAAP results exclude these investment gains and losses, so non-GAAP diluted EPS declined only to $2.43 from $2.59.

  2. What drove the difference between segment performance?

    RMS grew revenue 7.9%, with organic growth of 6.5% due mainly to higher revenue for large research model products. DSA declined 2.3% (organic decline of 3.1%) on lower discovery and regulated safety assessment sales volume, and Manufacturing Solutions declined 3.1% (organic decline of 5.1%) on lower CDMO and Biologics Testing revenue, partly offset by Microbial Solutions.

  3. What changed in the 2025 guidance?

    The company narrowed its reported revenue growth and non-GAAP EPS ranges to the middle and upper ends of prior ranges, respectively. Non-GAAP EPS guidance is now $10.10 to $10.30. GAAP EPS guidance was lowered to $4.15 to $4.35 from $4.25 to $4.65, and the venture capital and strategic investment losses estimate was raised to $0.50 per share from about $0.17.

  4. How is management describing the market outlook?

    CEO James C. Foster said demand for the company's early-stage research and manufacturing products and services remains stable, and that positive signals suggest the industry may be on a path toward recovery. He added that sustained improvement will take time, that uncertainty remains in the healthcare sector, and that the company is remaining cautious.